It was shown that IFN signaling is a target of EZH2 suppression in cancer: EZH2 represses IFNγ target genes in prostate [264], colorectal [265], and melanoma [266] cancer cells, while pharmacological inhibition of EZH2 in melanoma results in the upregulated profile of IFNγ and IFN-α downstream targets [266]. The gene discussed is IFNG; the disease is cancer.